S5-Generalizability of results from randomized trials: A systematic overview of possible approaches Piet N. Post, PhD (Presenter) (Dutch Institute for Healthcare Improvement CBO, Utrecht, Netherlands); Gordon H. Guyatt (McMaster University, Hamilton, Ontario, Canada) PRIMARY TRACK: Evidence generation and synthesis SECONDARY TRACK: Evidence appraisal BACKGROUND (INTRODUCTION): Randomized controlled trials (RCTs) are the preferred source for recommendations on the effect of treatment. Unfortunately, patients participating in RCTs frequently differ in many aspects from the majority of patients seen in practice. Therefore, guideline developers have to decide whether the results are generalizable to the target population not represented in RCTs.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Discuss available methods used to decide on generalizability. 2. Provide guidance on how to decide whether the results are generalizable to the target population that was not represented in RCTs.
METHODS:
A systematic review of the literature was undertaken to identify methods that can be used to decide the circumstances under which the results from RCTs can be generalized to patients who were not represented in these trials.
RESULTS:
A frequently recommended approach is that the trial population should be representative of the broad patient group. Numerous exclusion criteria applied in trials would diminish the generalizability. To evaluate the extent of the generalizability, one would have to examine the inclusion and exclusion criteria of trials and infer from these whether the trial population was sufficiently representative. Other authors suggest, because of the inclusion of a broader range of patients, reliance on observational studies if no direct evidence for the target population is available. A different view is to apply the results of trials to patients in practice unless there is a compelling reason to believe the results would differ substantially as a function of particular characteristics of those patients. This approach is supported by empirical evidence that, in general, treatment effects seldom differ to an important extent across subgroups of patients.
DISCUSSION (CONCLUSION):
We propose this last approach, focusing on RCTs unless there is compelling reason not to do so. Compelling reasons will most often be found with respect to issues of rare adverse effects, for which observational studies are likely to provide the best estimates. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer
S6-Validation and modification of the Graphical
Appraisal Tool for Epidemiology (GATE) for appraising studies in evidence-based guideline development Anita Fitzgerald (Presenter) (New Zealand Guidelines Group, Auckland, New Zealand); Jessica Berentson-Shaw (New Zealand Guidelines Group, Wellington, New Zealand) PRIMARY TRACK: Evidence generation and synthesis SECONDARY TRACK: Evidence appraisal BACKGROUND (INTRODUCTION): The Graphical Appraisal Tool for Epidemiology (GATE) is a set of five critical appraisal tools developed by the EPIQ collaboration in New Zealand comprising systematic reviews, intervention studies (randomized and nonrandomized), prognostic studies, and diagnostic studies. These tools were developed primarily for teaching purposes.
LEARNING OBJECTIVES (TRAINING GOALS):
1. To test inter-rater reliability for individual items on GATE checklists, to document reviewers' experience using GATE. 2. To modify GATE for use by the New Zealand Guidelines Group (NZGG) in guideline development. METHODS: Each study design was evaluated in two rounds; two reviewers independently completed GATE checklists from sample studies included in clinical practice guidelines. Agreement between reviewers was calculated for each item using prevalence-adjusted bias-adjusted kappa (PABAK) and reviewers' experiences of using the tool were documented.
